Enhanced superhyperfine structure of the EPR spectra of a U3+ ion introduced into the Van Vleck paramagnet LiTmF4

The observation of the superhyperfine structure (SHFS) in EPR spectra due to enhanced nuclear magnetism is reported. The X-band spectrum of a U 3+ ion introduced into the Van Vleck paramagnet LiTmF4 is measured in the temperature range of 5-20 K and compared with the spectra of LiLuF4:U3+ and LiYF4:U3+ single crystals. The spectra reveal well-resolved and strikingly different SHFS. The SHFS of Li(Lu, Y)F4:U3+ is due to the fluorine ions forming the nearest surroundings of the U3+ ion. The main contribution to the SHFS of the U3+ spectrum in LiTmF4 comes from the Tm3+ ions with a highly enhanced nuclear gyromagnetic tensor. © 2008 Pleiades Publishing, Ltd

Superhyperfine structure of the EPR spectra of Nd3+ and U3+ ions in LiRF4 (R = Y, Lu, Tm) double fluorides

The superhyperfine structure of the EPR spectra of impurity Nd3+ and U3+ ions in LiYF4, LiLuF4, and LiTmF4 double-fluoride single crystals has been observed and discussed. In LiYF4: Nd (g{pipe} = 1. 987, g⊥ = 2. 554) and LiTmF4: Nd, the superhyperfine structure is observed at the orientation of the external magnetic field B in parallel to the c axis of the crystals and consists of nine components with a splitting of ~15. 4 MHz. In LiYF4: U (g{pipe} = 1. 149, g⊥ = 2. 508) and LiLuF4: U, the superhyperfine structure is observed at both B {pipe} c and B ⊥ c and consists of nine and eleven components, respectively, with a splitting of ~21. 5MHz. It should be noted that the resolution of the superhyperfine structure of the EPR spectrum of LiLuF4: U3+ becomes significantly higher with a deviation from the orientation B ⊥ c. © 2011 Pleiades Publishing, Ltd

書評 八田達夫著 『消費税はやはりいらない』

The superhyperfine structure of the EPR spectra of impurity Nd3+ and U3+ ions in LiYF4, LiLuF4, and LiTmF4 double-fluoride single crystals has been observed and discussed. In LiYF4: Nd (g{pipe} = 1. 987, g⊥ = 2. 554) and LiTmF4: Nd, the superhyperfine structure is observed at the orientation of the external magnetic field B in parallel to the c axis of the crystals and consists of nine components with a splitting of ~15. 4 MHz. In LiYF4: U (g{pipe} = 1. 149, g⊥ = 2. 508) and LiLuF4: U, the superhyperfine structure is observed at both B {pipe} c and B ⊥ c and consists of nine and eleven components, respectively, with a splitting of ~21. 5MHz. It should be noted that the resolution of the superhyperfine structure of the EPR spectrum of LiLuF4: U3+ becomes significantly higher with a deviation from the orientation B ⊥ c. © 2011 Pleiades Publishing, Ltd

Superhyperfine structure of EPR spectra in LiLuF 4:U 3+ and LiYF 4:Yb 3+ single crystals

Electron paramagnetic resonance (EPR) spectra of doped paramagnetic crystals LiLuF 4:U 3+ and LiYF 4:Yb 3+ have been investigated at a frequency of about 9.42 GHz in the temperature range of 10-20 K. The U 3+ ion spectrum is characterized by g-factors g ∥ = 1.228 and g ⊥ = 2.516, and contains the hyperfine structure due to the 235U isotope with nuclear spin I = 7/2 and natural abundance of 0.71%. The observed hyperfine interaction constants are A ∥ = 81 G and A ⊥ = 83.8 G. Moreover, the spectrum reveals the well-resolved superhyperfine structure (SHFS) due to two groups of four fluorine ions forming the nearest surrounding of the U 3+ ion. This SHFS contains up to nine components with the spacing between components being about 12.7 G. The SHFS is observed also in the EPR spectrum of the LiYF 4:Yb 3+ crystal; up to 17 components with spacing of about 3.7 G may be traced. Some parameters of the effective Hamiltonian of the SHF interaction are estimated, the contribution of covalent bonding of f-electrons with ligands into these parameters is discussed. © 2008 Springer-Verlag

Superhyperfine structure of the EPR spectra of Ce3+ ions in LiRF4 (R = Y, Lu, Tm) double fluorides

The EPR spectra of Ce3+ impurity ions in LiYF4, LiLuF4, and LiTmF4 double-fluoride single crystals have been investigated at a frequency of ~9.3 GHz in the temperature range 5-25 K. The effective g factors of the ground Kramers doublet of the cerium ions in three crystals are close to each other (g{norm of matrix} = 2.737, g⊥ = 1.475 for LiYF4:Ce3+). A superhyperfine structure of the EPR spectrum of Ce3+ ions in the LiTmF4 Van Vleck paramagnet has been observed in the external magnetic field B oriented along the crystallographic axis c (B {norm of matrix} c). The superhyperfine structure of the EPR soectra of the Ce3+ ions in the LiYF4 and LiLuF4 diamagnetic matrices is resolved for B ⊥ c. Possible factors responsible for this pronounced difference in the properties of the systems studied have been discussed. © 2010 Pleiades Publishing, Ltd

Результаты клинического исследования препаратов Траумель® С и Цель® Т у пациентов с остеоартритом коленного сустава, имеющих сопутствующие сердечно-сосудистые заболевания

   Objective: to evaluate the efficacy and safety of simultaneous intramuscular administration of Traumeel® S and Zeel® T followed by therapy with the tablet medication Zeel® T in patients with knee osteoarthritis (OA) and concomitant cardiovascular diseases.   Material and methods. The analysis included 119 patients aged 45–79 years (78.2 % women and 21.8 % men) with confirmed diagnosis of knee OA according to Altman criteria, stage II–III according to Kellgren–Lawrence and confirmed cardiovascular disease. The main indicator of efficacy was the change in pain intensity in the target knee joint according to the “Pain” subscale of the WOMAC questionnaire (A) at the final examination compared to the baseline. Other criteria were the dynamics of each symptom of knee OA according to the WOMAC questionnaire (pain, stiffness, and functional impairment, total score) on each visit, pain intensity in the target joint on a visual analogue scale (VAS), time it takes to travel 15 m, and the patient's overall disease assessment on the VAS. In addition, duration of use and dose of paracetamol (if used) were assessed, as well as quality of life by EuroQol and adverse events (AEs). Treatment safety was also analyzed in patients who had received at least one dose of the study drug.   Results and discussion. WOMAC pain intensity decreased by on average of 3.8 points: from 7.6 to 3.8 points (95 % confidence interval, CI from -4.3 to -3.3). Data on changes in knee OA symptoms (pain, stiffness, and functional impairment) for each WOMAC subscale and the total score showed significant improvement at each follow-up visit (p < 0.0001). The VAS pain level decreased by 52%. An improvement in joint function was noted: the time it takes to travel 15 m fell from 19.5 to 16.4 s (p < 0.0001). The EuroQol quality of life score also improved from 57.1 ± 16.2 points at baseline to 71.1 ± 14.8 points on the 84<sup>th</sup> day of therapy. Thirty (25.2 %) patients had AEs, mainly neurological: headache (7.6 %) and hypoesthesia (1.7 %). No serious AEs were recorded. An association between AEs and study drug use was noted in 4 patients (headache, hypoesthesia, muscle cramps, and injection site pain).   Conclusion. The results of the study confirm the efficacy and safety of the use of Traumeel® S and Zeel® T in patients with knee OA who have concomitant cardiovascular disease. During therapy, a significant decrease in pain and other clinical signs of OA (stiffness, limitation of physical activity) was observed, which allows us to recommend this treatment regimen for patients with comorbid pathology, as well as with the risk of developing of AEs during non-steroidal anti-inflammatory drugs therapy.   Цель исследования – оценить эффективность и безопасность совместного внутримышечного введения Траумель® С и Цель® Т с последующей терапией таблетированным препаратом Цель® Т у пациентов с остеоартритом (ОА) коленного сустава (КС), имеющих сопутствующие сердечно-сосудистые заболевания.   Материал и методы. В анализ включено 119 пациентов 45–79 лет (78,2 % женщин и 21,8 % мужчин) с подтвержденным диагнозом ОА КС по критериям Альтмана, II–III стадией по Kellgren–Lawrence и подтвержденным заболеванием сердечно-сосудистой системы. Основным критерием эффективности было изменение интенсивности боли в целевом КС по субшкале «Боль» опросника WOMAC (A) на завершающем визите по сравнению с исходным уровнем, а дополнительными – динамика отдельных симптомов ОА КС по опроснику WOMAC (боль, скованность и функциональная недостаточность, суммарный индекс) при каждом визите, интенсивность боли в целевом КС по визуальной аналоговой шкале (ВАШ), время прохождения 15 м и общая оценка заболевания пациентом по ВАШ. Кроме того, оценивались продолжительность приема и доза парацетамола (если он использовался), а также качество жизни по EuroQol и нежелательные явления (НЯ). Проведен также анализ безопасности терапии у пациентов, получивших хотя бы одну дозу исследуемого препарата.   Результаты и обсуждение. Интенсивность боли по WOMAC снизилась в среднем на 3,8 балла: с 7,6 до 3,8 балла (95 % доверительный интервал, ДИ от -4,3 до -3,3). Данные об изменении симптомов ОА КС (боль, скованность и функциональная недостаточность) по каждой подшкале WOMAC и суммарный индекс свидетельствовали о значимом улучшении (p < 0,0001) при каждом последующем визите. Уровень боли по ВАШ уменьшился на 52 %. Отмечено улучшение функциональной способности суставов: изменение времени прохождения 15 м (p < 0,0001) с 19,5 до 16,4 с. Оценка качества жизни по EuroQol также улучшилась с 57,1 ± 16,2 балла исходно до 71,1 ± 14,8 балла на 84-й день терапии. У 30 (25,2 %) пациентов возникли НЯ, в основном со стороны нервной системы: головная боль (7,6 %) и гипестезия (1,7 %). Серьезных НЯ не зарегистрировано. Связь НЯ с приемом исследуемого препарата выявлена у 4 пациентов (головная боль, гипестезия, мышечные спазмы и боль в месте инъекции).   Заключение. Результаты исследования подтвердили эффективность и безопасность применения препаратов Траумель® С и Цель® Т у пациентов с ОА КС, имеющих сопутствующие сердечно-сосудистые заболевания. На фоне терапии отмечено значимое уменьшение боли и других клинических признаков ОА (скованности, ограничения физической активности), что позволяет рекомендовать данную схему лечения для пациентов с коморбидной патологией, а также с риском развития НЯ при приеме нестероидных противовоспалительных препаратов

Coulomb breakup of neutron-rich 29,30^{29,30}Na isotopes near the island of inversion

First results are reported on the ground state configurations of the neutron-rich $^{29,30}$Na isotopes, obtained via Coulomb dissociation (CD) measurements as a method of the direct probe. The invariant mass spectra of those nuclei have been obtained through measurement of the four-momentum of all decay products after Coulomb excitation on a $^{208}Pb$ target at energies of 400-430 MeV/nucleon using FRS-ALADIN-LAND setup at GSI, Darmstadt. Integrated Coulomb-dissociation cross-sections (CD) of 89 $(7)$ mb and 167 $(13)$ mb up to excitation energy of 10 MeV for one neutron removal from $^{29}$Na and $^{30}$Na respectively, have been extracted. The major part of one neutron removal, CD cross-sections of those nuclei populate core, in its' ground state. A comparison with the direct breakup model, suggests the predominant occupation of the valence neutron in the ground state of $^{29}$Na${(3/2^+)}$ and $^{30}$Na${(2^+)}$ is the $d$ orbital with small contribution in the $s$-orbital which are coupled with ground state of the core. The ground state configurations of these nuclei are as $^{28}$Na_{gs (1^+)\otimes\nu_{s,d} and $^{29}$Na$_{gs}(3/2^+)\otimes\nu_{ s,d}$, respectively. The ground state spin and parity of these nuclei, obtained from this experiment are in agreement with earlier reported values. The spectroscopic factors for the valence neutron occupying the $s$ and $d$ orbitals for these nuclei in the ground state have been extracted and reported for the first time. A comparison of the experimental findings with the shell model calculation using MCSM suggests a lower limit of around 4.3 MeV of the sd-pf shell gap in $^{30}$Na.Comment: Modified version of the manuscript is accepted for publication in Journal of Physics G, Jan., 201

Preliminary analysis of risk factors of osteoporosis in postmenopausal women with essential hypertension

The problem of relationship between cardiovascular diseases and an osteoporosis is actual now. The aim of this research was to study the factors associated with osteoporosis in postmenopausal women with essential hypertension. Materials and methods: 166 women, middle age 62,7±6,34. Inclusion criteria: the age of 50 years and more: postmenopause more than 1 year; the established diagnosis of essential hypertension; absence of the reasons for a secondary osteoporosis. The next exams were done: x-ray densitometry of lumbar spine and hip, X-ray examination, ultrasound of carotid arteries, level of plasma creatinine and general cholesterol. Results: Prevalence of an osteoporosis and osteopenia was similar as in population (osteoporosis at 21 (12,65±2,58%) women, osteopenia 39 (23,49±3,29%), norm — 106 (63,86±3,73%)). The fractures after low trauma were revealed at 30 (18,07±2,98%) women. We haven't received the relationship between various characteristics of essential hypertension, treatment of hypotensive therapy and prevalence of osteoporosis and fractures. During the analysis of risk factors of osteoporosis and cardiovascular complications it has been received that fractures meet at persons with BMI> 25 kg/m2 (p 25 кг/м2 (р<0,005). Возраст старше 65 лет является значимым фактором риска как сердечно-сосудистых осложнений, так и остеопороза (р<0,00001). Осложнения гипертонической болезни со стороны сосудов головного мозга чаще встречались у лиц с остеопорозом (при оценке критерия Пирсона для транзиторных ишемических атак р=0,01, для ОНМК р=0,03), что не противоречит данным литературы. Выводы: исследование демонстрирует корреляцию между частотой осложнений со стороны сосудов головного мозга у женщин с гипертонической болезнью и частотой остеопороза

Resolution on the results of the First All-Russian Forum "Therapeutic Education in Endocrinology"

According to the decision of the WHO, therapeutic education (TE) of patients is an independent branch of medicine and an essential component of the treatment of chronic diseases, primarily diabetes mellitus and obesity. TE is implemented through the creation of “Schools for patients with diabetes mellitus” and “Schools for patients with overweight” (“Schools”) as a structural unit of a medical institution. On April 25–26, 2022, the First All-Russian Forum «Therapeutic Education in Endocrinology» was held online, organized by the Public Organization «Russian Association of Endocrinologists», which was attended by leading experts in this field. As a result of its work, this Resolution was adopted by the experts. It discusses the methodological and pedagogical foundations of TE, it is proposed to make changes related to the organization of the work of «Schools», tariffing in the obligatory health insurance system, and training of personnel, including nurses